SAN FRANCISCO, CA--(Marketwire - October 04, 2012) -
Zenmark announced today their role in the development of the brand name REVESTIVE (teduglutide), a new therapy for Short Bowel Syndrome (SBS). "Pharmaceutical naming is often fraught with peril & frustration due to global health authority constraints. Gaining approval for such a powerfully aspirational name such as Revestive is what makes this job truly special," said Greg Balla, President & Creative Director of Zenmark. "As a U.S.-based agency, we're particularly proud of global and ex-U.S. marks that resonate in markets worldwide," Balla added.
REVESTIVE has been granted an orphan drug designation by the FDA and the European Medicines Agency (EMA) and received a positive CHMP opinion by the EMA on June 22, 2012. The marketing authorisation application was submitted in March 2011. Takeda has partnered with NPS Pharmaceuticals on the new product and holds the distribution rights for teduglutide in Europe where the medicinal product will be known as REVESTIVE.
Zenmark® is the industry's first Verbal Design Agency, a leading naming and branding firm based in San Francisco, CA. Since opening its doors in 1999, Zenmark® has provided premium corporate identities, product/service names, and taglines/slogans in a wide range of markets including; pharmaceuticals and life sciences; information technology; consumer electronics; security; travel services, and consumer packaged goods. Recent clients include General Motors, Dell, Novartis, Bristol-Myers Squibb, Eli Lilly and GlaxoSmithKline. For further information please call 415-434-4800 or Web site: www.zenmark.com email: email@example.com
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing orphan products to patients with rare disorders and few, if any, therapeutic options. NPS is advancing two late-stage registration programs. A New Drug Application is undergoing FDA review for Gattex® (teduglutide) as a treatment for adult short bowel syndrome (SBS) and a Phase 3 registration study has been completed for Natpara™ -- recombinant human parathyroid hormone (rhPTH [1-84]) -- in adult hypoparathyroidism. NPS' earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Nycomed (acquired by Takeda Pharmaceutical Company Limited).